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ABSTRACT 
Introduction: Retained placenta is one of major cause for postpartum haemorrhage. Various medication and routes 
of administration have been reported to increase spontaneous placenta delivery and prevent manual removal of 
placenta. Purpose of the study to compare the outcome between misoprostol and oxytocin in management of retained 
placenta.  
Method: literature searching was done in 4 databases (Pubmed, EbscoHost, Cochrane and Scopus) with specific 
keywords, continued with article selection and critical appraisal.   
Result: 5 randomized controlled trial articles were found match to eligibility criteria. 3 of 5 studies found that 
spontaneous placental delivery occurred more in misoprostol group than oxytocin group. Based on 2 studies, the NNT 
value of misoprostol are 3 compare to oxytocin group. 2 other studies found that no significant differences of 
spontaneous delivery of placenta in misoprostol and oxytocin group. 2 studies found that misoprostol had shorter time 
for spontaneous placenta delivery. However, 2 other studies also found that misoprostol had longer time for 
spontaneous delivery. 1 study also found that Misoprostol group have less blood loss than oxytocin group.  
Conclusion: administration of misoprostol has better outcome in induce spontaneous placenta delivery, time needed 
for delivery and less blood loss volume compared to oxytocin. 
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INTRODUCTION 
Postpartum haemorrhage is the most 
common cause of maternal mortality in Indonesia 
and worldwide.1 In Indonesia, 30.3% of maternal 
mortality are caused by postpartum 
haemorrhage. Prolonged third stage labour or 
retained placenta is one of major cause for 
postpartum haemorrhage.2  Retained placenta 
define as a condition when a placenta didn’t 
deliver after 30 minutes of active management or 
60 minutes of physiological management of third 
stage labour. Retained placenta occur in 2-3.3% 
of vaginal delivery.3  
Despite of those fact, there is still no standard 
of care for management of prolonged third stage 
labour.3 Manual removal of placenta (MROP) is 
currently the treatment of choice and the 
definitive treatment for retained placenta. 
However, MROP has more risk for infection 
(endometritis), haemorrhage, and traumatic 
uterine perforation.4 
Various medication and routes of 
administration have been reported to increase 
spontaneous placenta delivery and prevent 
manual removal of placenta. Those medication 
called uterotonics agent. Uterotonics agent can 
stimulate the contraction of myometrium to 
induce the separation of placenta.3 World health 
organization (WHO) have recommended the use 




of uterotonics agent for retained placenta.5 Based 
on various research, oxytocin and misoprostol in 
one of the most promising and common 




A 25 years old pregnant women (G1P0) at 38 
weeks gestation was came to emergency 
obstetrics and gynaecology unit. The patient was 
delivered a viable male infant via vaginal delivery. 
After the delivery of infant (second stage of 
labour), 10 IU oxytocin was administrated via 
intramuscular injection in 1/3 medial vastus 
lateralis muscle, but 30 minutes after the injection 
the placenta wasn’t delivered yet. The physician 
though that the women had retained placenta. 
The ultrasonography (USG) before the delivery 
show normal placenta attachment that there was 
no placenta accrete, increta nor percreta.  The 
patient doesn’t have comorbid such as 
hypertension, diabetes, or infection. The patient 
have normal vital sign and mild bleeding (±150 
ml). The physician wants to use uterotonic drugs 
to induce spontaneous delivery of placenta. But 
the physician confused which drugs that will have 




In women with retained placenta, does 
administration of misoprostol have better 
outcome in induce spontaneous delivery of 
placenta compared to oxytocin? 
 
METHODS 
The article searching was done in 4 
databases including Pubmed, EBSCOHost, 
Cochrane and Scopus. The keywords or terms 
that has been use for article searching strategy 
are “retained placenta”, “misoprostol”, “oxytocin” 
and “syntocinon’. The keywords were arranged 
with Boolean Method.  Literature searching was 
done on November 27th to 29th 2020.    
Article selection consist of screening of title 
and abstract, removal of duplication, and article 
selection based on the full text.  Selection of the 
article title, abstract, and full text are based on 
eligibility criteria. The article which cannot full pill 
the eligibility criteria will be excluded. 
The inclusion criteria of this study were 
randomized control trial (RCT) or systematic 
review/meta-analysis of RCT studies; women 
women with retained placenta and singleton 
pregnancy as study population; administration of 
misoprostol as the intervention group and 
oxytocin for the comparison; spontaneous 
delivery of placenta, time needed for placental 
delivery, or incident of manual removal placenta 
as the outcome. Meanwhile, the exclusion criteria 
of this study were not-accessible full text, 
unfinished studies and not using english or 
Indonesia language. 
the critical appraisal tools that has been used in 
this study are based on Centre for Evidence-
Based Medicine (CEBM) for RCT study which 





Total of articles that match with the keywords 
are 187 articles from four database (Pubmed 23 




articles, EbscoHost 19 articles, Cochrane 33 
articles, Scopus 112 articles). After the literature 
searching was done, the step continued with 
article selection. The illustration of article 
selecting is shown in PRISMA flowchart (Figure 
1). In final, only 5 articles were included in this 
study. Those articles consist of 4 randomized 
controlled trial study (Rogers et al., 2007; Harara 
et al., 2011; Nazerr et al., 2016; Maher et al., 
2017) and 1 double-blind randomized controlled 
trial study (Najafian et al., 2018). The level 
evidence criteria are based on Oxford Centre for 
Evidence-based Medicine 2009 for therapy 
study.6 The characteristics of each study can be 
seen at Table 1. The article that has been 
selected will continue to be critically appraised in 




Figure 1 PRISMA Flowchart 
 
Table 1 Study characteristics (Level of evidence) 




Women with singleton 
pregnancy at ≥37 weeks 
and prolonged 3rd stage of 
labour (>30 minutes) 
without significant 
bleeding. 
Misoprostol 800 mcg 
and Oxytocin 50 IU  




- Spontaneous placenta 
delivery or manual 
removal of placenta  








Women with singleton 
pregnancy at ≥20 weeks 
gestation and prolonged 
3rd stage of labour >30 
minutes, and 
hemodynamic stable  
Misoprostol 800 mcg 
and Oxytocin 20 IU  
in 30 ml saline 
intraumbilical 
injection 
- Spontaneous placenta 
delivery or manual 
removal of placenta  












All of 5 studies fulfil all the validity criteria that 
can be seen on Table 2. Randomization to 
allocate the participant has been done in all of 5 
studies. In Rogers et al. study, the randomization 
method was prospective randomization in 
participants that come to two obstetrics units in 
Hong Kong from 2004-2005. In Harara et al. 
study, the participant randomly allocated into 
each group and the randomization was done by 
a computer-generated system. In Nazeer et al. 
study, the randomization was done by randomly 
allocating the participant into each group with an 
envelope method. In Maher et al. study, the 
participant was allocated randomly into each 
group by trial sequence in a computer-generated 
system that developed by statistician. In Najafian 
et al. study, the participant was allocated 
randomly into each group, the method of 
randomization was not mentioned in the article.  
In all of 5 studies mentioned that there were no 
significant characteristic differences between the 
two group (p<0.05). In all of 5 studies also 
mentioned that all participant in each group was 
threated equally. In Rogers et al. study, each 
participant was given a prophylactic oxytocic 
drugs (Syntometrine 1 ml IM or Syntocinon 10 
unit IV) after the second stage of labour, the 
intervention was given if the placenta didn’t 
deliver spontaneously in 45 minutes via 
intraumbilical injection with Pipingas technique. 
In Harara et al. study, the intervention was given 
to the participant if the placenta didn’t deliver 
spontaneously in 25 minutes and if the separation 
occurred in the last 5 minutes the solution was 
discarded. The administration of the drug also via 
intraumbilical injection with Pipingas technique. 
In Nazeer et al. and Najafian et al. study, all of the 
intervention drugs was administrated via 
intraumbilical injection in 30 ml normal saline with 
Pipingas technique, and except for the kind of the 
drug that administrated, all of the procedure are 
the same in each group participant. In Maher et 
al. study, apart from the kind of the drugs and 
administration route of the drugs, there was no 
different procedure between two group. In all of 5 
studies, the number of participants that has been 
Nazeer et 
al., 20169 
Women with singleton 
pregnancy at ≥37 weeks 
gestation, prolonged 3rd 
stage labour (>30 
minutes), and 
hemodynamic stable 
Misoprostol 800 mcg 
and Oxytocin 50 IU  
in 30 ml saline 
intraumbilical 
injection 
- Spontaneous placenta 
delivery or manual 
removal of placenta  
- Time needed for placenta 
delivery 






Woman with singleton 
pregnancy and prolonged 
3rd stage of labour (>30 
minutes) and 
hemodynamic stable. 
Misoprostol 400 ug 
sublingual and  
Oxytocin 30 IU in 30 
ml normal saline 
intraumbilical 
injection 
- Spontaneous placenta 
delivery or manual 
removal of placenta  
- Time needed for placenta 






Pregnant women who 
have a normal first and 
second stage labour but 
prolonged 3rd stage of 
labour (>30 minutes) and 
hemodynamic stable. 
Misoprostol 800 mcg 
and Oxytocin 50 IU  
in 30 ml saline 
intraumbilical 
injection 
- Spontaneous placenta 
delivery or manual 
removal of placenta  
- Time needed for placenta 









allocated into each group was same with the 
participants that entered analysis procedure. In 
Rogers et al. study, there were 1 failed 
catheterization sample in each group. In Maher et 
al study there were 3 failed administration drugs 
in Misoprostol group and 4 in oxytocin group. All 
that sample was count into failed treatment 
group. All of 5 studies were fulfil the blinding  
criteria. In Rogers et al and Nazeer et al study, 
the blinding was done only in the participants. In 
Najafian et al. study, the blinding was done 
double in participant and person that 
administrated the drugs. In Harara et al, study 
although it didn’t mention about blinding, but the 
study has objective outcome and all the drugs 
was administrated intraumbilical injection in 30 ml 
saline, so it fulfils the blinding criteria. In Maher et 
al. study, the blinding was done by hide the 
assignment for a single patient in opaque 
sequenced envelopes.         
 
Table 2 Validity of the study 
 
Importance 
Importance of the studies can be calculated in all 
of 5 studies because all the article mentioned the 
exact number of intervention and outcome group. 
The importance of each study can be seen on 
Table 3. 3 of 5 studies (Rogers et al, Nazeer et al 
and Najafian et al) found that misoprostol had a 
better outcome in spontaneous placental delivery 
than oxytocin group.  The rest of the studies 
(Harara et al and Maher et al) found there are no 
significant difference between misoprostol and 
oxytocin in induce spontaneous placental 
delivery. In Rogers et al and Najafian et al studies 
has significant relative risk, but in Nazeer et al 
studies the relative risk was not significant 
although the difference outcome between 
misoprostol and oxytocin group was significant 
(p<0.05). The absolute risk reduction of 
misoprostol group from oxytocin group are 
37.14% in Rogers et al study and 40.91% in 
Najafian et al study. These result show that 
administration of misoprostol can reduce 37.14% 
or 40.91% manual removal of placenta risk 
compare to administration of oxytocin. Number 
need to treat of misoprostol to reduce 1 manual 
removal of placenta compare to oxytocin are 3 in 
Rogers et al and Najafian study. These result 
means that if 3 patients with retained placenta or 
prolonged third stage of labour were threat with 








Rogers et al., 2007 + + + + + 
Harara et al., 2011 + + + + + 
Nazeer et al., 2016 + + + + + 
Maher et al., 2017 + + + + + 
Najafian et al., 2018 + + + + + 




misoprostol it will reduce 1 manual removal of 
placenta procedure compare to if the patient were 
threat with oxytocin.  
Aside from spontaneous delivery or manual 
removal of placenta, the outcome of these 5 
studies also compare the time needed for 
placental delivery between misoprostol and 
oxytocin group. In Rogers et al. study the 
misoprostol group has longer time for 
spontaneous placenta delivery compare to 
oxytocin group, but the study did not mention 
whether the differences significant or not. The 
time recorded in Rogers et al. study was total 3rd 
stage of labour not only after injection of 
intervention drugs. In Maher et al. study also 
mentioned that misoprostol group has longer time 
for spontaneous placenta delivery compare to 
oxytocin, and the difference are significant. 
Otherwise, in Harara et al. and Nazeer et al study 
found that misoprostol group has shorter time for 
spontaneous placenta delivery compare to 
oxytocin group, and the difference are significant. 
In Nazeer et al. study also found that misoprostol 




All of 5 articles/studies that used in this study was 
done in Asia country. 1 study (Rogers et al) was 
done in Hongkong, 2 studies (Harara et al and 
Maher et al) in Egypt, 1 study (Nazeer et al) in 
Pakistan, and 1 study (Najafian et al) in Iran. The 
subject in all of 5 studies are pregnant women 
with prolonged third stage of labour or retained 
placenta and hemodynamic stable. In Harara et 
al. study the subjects was women with preterm 
and a term singleton pregnancy (≥20 weeks 
gestation), but in Rogers et al. and Nazeer et al. 
study the subjects was only women with a term 
singleton pregnancy (≥37 weeks gestation). In 
Maher et al. and Najafian et al. study didn’t 
mention about the subjects gestational age. 
Based on Coviello et al study there are no 
difference risk of retained placenta in Middle East 
race, Asian and Indonesian race. Gestational age 
≥34 weeks tend to have lower risk compare to 24-
27 weeks gestation. The patient in this case 
illustration is a Woman with 38 weeks singleton 
pregnancy has prolonged third stage of labour 
and hemodynamic stable. The characteristic of 
the participants of those 5 studies and patient in 
this study are similar so this research can be 
applied to patient in case illustration.    
4 of 5 studies (Rogers et al., Harara et al., Nazeer 
et al., and Najafian et al.) are use intraumbilical 
injection of misoprostol and oxytocin, but 1 study 
(Maher et al.,) use sublingual misoprostol and 
intraumbilical injection of oxytocin. Intraumbilical 
injection has been applied in Indonesia but it 
needs skilled physicians or midwife or special 
training for intraumbilical injection. Misoprostol 
and oxytocin are common drugs that has been 
used widely in Indonesia. The preparation for 
misoprostol injection may be more difficult than 
oxytocin injection. Misoprostol only has tablet 
dosage form. Before it injected to umbilical vein, 
its need to be dissolve in normal saline under 
aseptic condition to reduce the risk for infection.  
Administration of misoprostol can cause adverse 
effects. Adverse effect that can be appear such 
as shivering, fever, dizziness, headache, 
vomiting, abdominal pain. In Nazeer et al. study 
mentioned that there was no significant adverse 
effect appear in misoprostol group compare to 




oxytocin group. Only 1 patient in misoprostol 
group that developed shivering and pyrexia. So, 
it can be concluded that the potential benefits of 
misoprostol administration in retained placenta 








Retained placenta define as a condition 
when a placenta didn’t deliver after 30 minutes of 
active management or 60 minutes of 
physiological management of third stage labour. 
Retained placenta occur in 2-3.3% of vaginal 
delivery. Prolonged third stage labour (retained 
placenta) is one major cause of postpartum 
haemorrhage.  Despite of those fact, there is still 
no standard of care for management of prolonged 
third stage labour. Various medication and routes 
of administration have been reported to increase 
spontaneous placenta delivery and prevent 
Importance  RR  
(95% CI) 




Time needed for 
delivery 
Blood loss 
















































































































Table 3 Importance of the study 




manual removal of placenta. Based on various 
research, oxytocin and misoprostol in one of 
promising drug for management of retained 
placenta.3  
Based on critical appraisal of those 5 RCT 
studies (Rogers et al., Harara et al., Nazerr et al., 
Maher et al. and Najafian et al.), It show that most 
of studies found that misoprostol was superior 
than oxytocin for retained placenta. 3 of 5 studies 
(Rogers et al., Nazeer et al., and Najafian et al.) 
found that spontaneous placental delivery 
occurred more in misoprostol group than oxytocin 
group. 2 other studies found that no significant 
differences of spontaneous delivery of placenta in 
misoprostol and oxytocin group. 2 studies 
(Harara et al. and Nazerr et al.) found that 
misoprostol had shorter time for spontaneous 
placenta delivery, but 2 other studies (Rogers et 
al. and Maher et al.) found that misoprostol had 
longer time for spontaneous delivery. In Nazeer 
et al. study, also found that Misoprostol group 
have less blood loss than oxytocin group.  
All those 5 studies are randomized 
controlled trial study. Each study fulfils validity 
criteria for therapy studies. Despite all of 5 studies 
fulfil the validity criteria, each study still has 
weakness. In general, there are difference 
dosage of oxytocin and difference dosage and 
form of misoprostol drugs which has been use in 
those 5 studies. In Harara et al. it only used 20 IU 
oxytocin which different from other studies that 
used 50 IU oxytocin. In Maher et al. study, it used 
400 mcg sublingual misoprostol and 30 IU 
oxytocin. Other 3 studies use 800 mcg 
misoprostol and 50 IU oxytocin that injected via 
umbilial vein. In Rogers et al study, it mentioned 
that they use (Syntometrine 1ml or Syntocinon 10 
IU) for active management third stage of labour. 
Those two different drugs may confound the 
misoprostol or oxytocin injection. In Harara et al. 
study, it didn’t differentiate preterm and term 
pregnancy analysis despite uterotonics response 
is less effective in preterm pregnancy.9 In Maher 
et al. and Najafian et al studies, both studies 
didn’t mention gestational age and in Najafian et 
al. didn’t mention singleton pregnancy. Others 
than Maher et al. study, 4 studies has small 
participants which range from 40-60 participants.   
Currently, there is no standard of care for 
management prolonged third stage labour. WHO 
guidelines in 2009 recommend repeat active 
management of oxytocin injection dose or 
oxytocin injection via umbilical vein.5 Manual 
removal of placenta is the definitive treatment for 
retained placenta but it has high risk for infection 
and increased bleeding.4 After critically appraised 
the literature, we recommend, the use of 
intraumbilical injection of misoprostol for retained 
placenta other than oxytocin. But further trial and 
research that included large participants are 
needed to determine the safest and most 
effective management for retained placenta 
especially use misoprostol as an intervention.  
 
CONCLUSION AND RECOMMENDATION 
In women with prolonged third stage labour or 
retained placenta, administration of misoprostol 
has better outcome in induce spontaneous 
placenta delivery compared to oxytocin. Injection 
of misoprostol also has shorter time and less 
blood loss. Route of administration of misoprostol 
that superior to oxytocin is intraumbilical injection. 
Outcome for sublingual misoprostol doesn’t have 
significant difference compare to intraumbilical 




oxytocin injection. We recommend, the use of 
intraumbilical injection of misoprostol for retained 
placenta other than oxytocin. However, further 
trial and research that included large participants 
are needed to determine the safest and most 
effective management for retained placenta 
especially use misoprostol as an intervention. 
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